Swiss Biotech – Industry news, events, directory, Swiss Biotech Association

Get the insight

Swiss Biotech Report 2026

How did we fare in 2025?

Our association in facts and figures

In print & digitally

The leading compedium of Swiss Biotech

Become a Member

Loads of reasons to join

Invest in Swiss biotechs

Discover investment and partnering opportunities

Talent meets opportunities

Become part of the thriving community

Create lasting business ties

Connect with the Swiss biotech ecosystem

Total revenues reached a record CHF 7.5 billion in 2025 (CHF 7.2 billion in 2024) with more companies maturing to the commercial stage and a continuously growing demand for specialized CDMO services. Funding increased by 2.1% to CHF 2.6 billion. In a notable shift, investments in privately funded companies achieved a record CHF 1.15 billion – an increase of 38% compared to 2024, and a record 45%
May 5, 2026

We are tracking and escalating fraud campaigns targeting Swiss Biotech Association members and Swiss Biotech Day participants. Multiple fraudulent domains and Gmail accounts have already been identified and reported to their registrars and hosts; several have been taken down, but new ones continue to appear. Please read this alert carefully and share it within your organization.
April 16, 2026

As Europe experienced one of its hottest Junes on record, with prolonged heatwaves reinforcing the urgency of climate action, leaders from the pharmaceutical industry and academia gathered in Zurich for the PharmaBlock’s 3rd Green Chemistry Symposium (GCS) to explore how green chemistry and process innovation can accelerate the decarbonization of pharmaceutical manufacturing.
August 7, 2026

People with AAE-C1INH experience frequent misdiagnoses, emergency medical events, and wide-ranging impact on physical, emotional, and social well-being Study results informed the design and endpoint selection of the ongoing Phase 3 CREAATE study
August 6, 2026

SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
August 4, 2026

Volv Global has been selected as a finalist in the 2026 Fierce AI Innovation Awards, in the category AI Innovation in Real-World Evidence & Data Analytics.
July 30, 2026

Celonic AG, a Swiss-based biologics Contract Development and Manufacturing Organization (CDMO), and Leukocare AG, a leading provider of drug product development services, today announced a collaboration to support biopharmaceutical companies developing increasingly complex biologics.
July 28, 2026